Literature DB >> 6448650

Event recording in a clinical trial of a new medicine.

R J Simpson, B Tiplady, D C Skegg.   

Abstract

In a double-blind trial of the effect of zimelidine on weight and appetite 24 obese patients were allocated at random to receive either zimelidine or placebo for eight weeks followed by the alternative treatment for eight weeks. Possible adverse effects were elicited by asking patients at weekly intervals whether they had experienced any symptoms or ailments and recording all such "events" on a special form. A conventional checklist of symptoms was also used. Among 19 patients who completed the trial the two methods of recording yielded similar patterns of events. Of symptoms not on the checklist, insomnia was more common during treatment with zimelidine. Event recording was found to be a practicable and convenient method of detecting possible adverse effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6448650      PMCID: PMC1601155          DOI: 10.1136/bmj.280.6223.1133

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Recording events in clinical trials.

Authors:  M Weintraub
Journal:  Br Med J       Date:  1978-03-04

2.  The case for recording events in clinical trials.

Authors:  D C Skegg; R Doll
Journal:  Br Med J       Date:  1977-12-10

3.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

4.  Zimelidine: a therapeutic and pharmacokinetic study in depression.

Authors:  A Coppen; V A Ramo Rao; C Swade; K Wood
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

5.  Preliminary clinical test of zimelidine (H 102/09), a new 5-HT uptake inhibitor.

Authors:  A Aberg; G Holmberg
Journal:  Acta Psychiatr Scand       Date:  1979-01       Impact factor: 6.392

  5 in total
  6 in total

1.  Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Authors:  M C Reilly; A S Zbrozek
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

2.  Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.

Authors:  W Schiess; D Welzel; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Effect of zimelidine, a new antidepressant, on appetite and body weight.

Authors:  R J Simpson; D J Lawton; M H Watt; B Tiplady
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

4.  Adverse event monitoring in clinical trials of felodipine and omeprazole.

Authors:  M A Wallander; P Lundborg; K Svärdsudd
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  A study of the effects of zimelidine on the pharmacokinetics and pharmacodynamics of temazepam in healthy volunteers.

Authors:  D Fagan; D B Scott; B Tiplady
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 6.  Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R C Heel; P A Morley; R N Brogden; A A Carmine; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.